Lebrikizumab (Ebglyss)

What is lebrikizumab?

Lebrikizumab (Ebglyss) is an injectable biologic medication used in dermatology for moderate-to-severe atopic dermatitis. It is a targeted treatment designed to reduce inflammation and itch in patients whose eczema is not adequately controlled with topical treatment alone or when topical therapy is not a good fit.

How does lebrikizumab work?

Lebrikizumab targets interleukin-13 (IL-13), one of the key inflammatory signals involved in atopic dermatitis. By reducing IL-13 activity, lebrikizumab can help calm inflammation, improve the skin barrier, and reduce itching.

What are possible side effects of lebrikizumab?

Possible side effects can include:

  • Eye irritation or conjunctivitis

  • Injection site reactions

  • Itching or irritation around the eyes

Many patients tolerate treatment well, but side effects and monitoring should always be reviewed with the prescribing clinician.

How is lebrikizumab used?

Lebrikizumab is given by injection on a schedule directed by your provider. Some patients may be able to self-inject after proper training. The medication is typically stored in the refrigerator.

This treatment is often considered for patients with eczema that is more widespread, more persistent, or having a greater effect on sleep, comfort, or quality of life.

THIS CONTENT IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES AND MAY NOT BE COMPREHENSIVE. IT DOES NOT CONSTITUTE MEDICAL ADVICE. PLEASE REFER TO OUR TERMS OF USE FOR FURTHER DETAILS. ALWAYS CONSULT WITH YOUR HEALTHCARE PROVIDER BEFORE MAKING ANY MEDICAL DECISIONS.